106 patients were screened

26 had laboratory tests outside of the acceptable range
11 had unacceptable medical histories
3 had used excluded medications or therapies
1 had a current infection

65 patients underwent randomization

34 patients were assigned to receive TwHF treatment
1 patient had a severe adverse event (WBC count < 2.5×10^9/L)
4 patients were lost to follow-up
29 TwHF patients completed the study

31 patients were assigned to receive valsartan treatment
1 patient had a severe adverse event (K⁺ > 6.5 mmol/L)
4 patients were lost to follow-up
26 valsartan patients completed the study

Figure 1. Flowchart of the treatment of DN with TwHF or valsartan